Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Swine mycoplasma pneumonia inactivated vaccine and preparation method thereof

A technology of Mycoplasma swine pneumonia and inactivated vaccines, which is applied in the direction of bacterial antigen components, oil/fat/wax non-effective ingredients, antibacterial drugs, etc., can solve the problems of complicated operation and difficult promotion, and achieve good spirits, strong immune effects, The effect of reducing dosage

Active Publication Date: 2015-03-11
哈药集团生物疫苗有限公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the attenuated live vaccine for the prevention of mycoplasma pneumonia in swine has complex operations and is not easy to promote. It is urgent to develop an inactivated vaccine for mycoplasma pneumonia in swine that is simple to operate and can improve the humoral immune response and enhance the immune effect after immunization of animals

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Swine mycoplasma pneumonia inactivated vaccine and preparation method thereof
  • Swine mycoplasma pneumonia inactivated vaccine and preparation method thereof
  • Swine mycoplasma pneumonia inactivated vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] The preparation of embodiment 1 swine mycoplasma pneumonia inactivated vaccine

[0025] 1. Strain characteristics

[0026] 1.1 Morphological and biochemical properties

[0027] Mycoplasma hyopneumoniae P-5722-3 strain, the shape of the bacteria is ring-shaped, spherical, filamentous, rod-shaped or point-shaped polymorphic microorganisms, without cell walls, and Gram staining is negative.

[0028] 1.2 Culture characteristics

[0029] In the Lps liquid medium, cultured at 37°C for 5-10 days, the pH value of the medium dropped below 0.5 and appeared slightly turbid; on the solid medium, cultured at 37°C with 5% CO 2 Cultivate in a humid environment for 7 to 10 days, gray-white mycoplasma colonies can be seen under a low-power microscope. Most of the colonies have neat edges, a few colonies have irregular edges, and most of the colonies do not have "umbilical" features in the middle.

[0030] 1.3 Serological characteristics

[0031] It is identified by metabolic inhibi...

Embodiment 2

[0043] The safety test of embodiment 2 swine mycoplasma pneumonia inactivated vaccine

[0044] According to the preparation method of Example 1 of the present invention, 3 batches of inactivated vaccines for mycoplasma pneumonia were trial-produced, and the safety tests of non-target animals, single dose, overdose and single dose repeated injection were carried out respectively for the 3 batches of inactivated vaccines for trial-produced mycoplasma pneumonia .

[0045] 1. Safety test of inactivated vaccine against Mycoplasma pneumoniae in non-target animals

[0046] For the safety test of mice, 3 batches of trial-produced vaccines were subcutaneously injected into 8 mice weighing 14-24g, each with 0.5ml. At the same time, a normal saline immunization control group was set up and observed for 14 days to observe whether there were any adverse reactions caused by the vaccine.

[0047] The results are shown in Table 1. The vaccinated mice did not have any adverse reactions, and a...

Embodiment 3

[0066] The immunity test of embodiment 3 swine mycoplasma pneumonia inactivated vaccine

[0067] According to the preparation method of Example 1 of the present invention, 3 batches of inactivated vaccines against Mycoplasma swine pneumonia were trial-produced.

[0068] 1. Determination of the immune effect of inactivated vaccines

[0069] Three batches of trial-produced inactivated vaccines for Mycoplasma hyopneumoniae were used to intramuscularly inject 10 healthy susceptible pigs each with negative serum antibody against Mycoplasma hyopneumoniae, each with 2.0ml, and another 10 pigs were injected with normal saline as control pigs. 14 days after the injection, the same dosage was used for the second immunization. All experimental pigs were managed according to conventional feeding, and the piglets were weaned at the age of 24 days and transferred to the fattening house at the age of 65 days. After immunization, the birth weight, weaning weight, and slaughter weight of eac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a swine mycoplasma pneumonia inactivated vaccine and a preparation method thereof and belongs to the field of swine mycoplasma pneumonia inactivated vaccines. The swine mycoplasma pneumonia inactivated vaccine comprises a water phase and an oil phase according to a volume ratio of 1: 1-3. The water phase comprises Tween-80 and swine pneumoniae mycoplasma liquid according to a ratio of 2-5: 95-98. The oil phase comprises polyoxyl-40-hydrogenated castor oil, Span-80 and white oil according to 1-2: 5-8: 90-94. The invention further discloses a method for preparing the swine mycoplasma pneumonia inactivated vaccine. An emulsification adjuvant of the swine mycoplasma pneumonia inactivated vaccine is added with polyethyleneglycol-40-hydrogenated castor oil with hydrophilic and hydrophobic groups, substantially improves vaccine emulsification effects, substantially reduces a use amount of white oil and vaccine consistency, reduces injection difficulty and animal stress response, realizes a high antibody level in a long period and has substantial immunization effects on piglets.

Description

technical field [0001] The invention relates to an inactivated vaccine, in particular to an inactivated vaccine for mycoplasma pneumoniae in swine, and further relates to a method for preparing the inactivated vaccine for mycoplasma pneumoniae in swine, which belongs to the field of preparation of inactivated vaccine for mycoplasma pneumoniae in swine. Background technique [0002] Mycoplasma pneumonia in swine is a chronic pneumonia caused by Mycoplasma hyopneumoniae, also known as porcine endemic pneumonia. , and reproduced the disease in the laboratory, the pathogen was named M.hyopneumoniae after the report. For a long time, this disease has been considered as one of the most common, most widespread and most difficult to purify important diseases that cause great economic losses to the pig industry. Although the disease is an old disease, its importance has been highlighted in recent years because it is often mixed with other pathogens such as porcine blue ear disease v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/02A61K47/44A61P31/04
Inventor 梁宛楠丁国杰刘洪斌张智明王全杰毛春玲孙凯张祎李莉莉冯闻迪
Owner 哈药集团生物疫苗有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com